We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$283M
AUM Growth
+$29.2M
Cap. Flow
+$33.3M
Cap. Flow %
11.77%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.3M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$17

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$104M 36.87%
852,708
– –
RLYB icon
2
Rallybio
RLYB
$87M
$39.9M 14.11%
+283,914
New +$33.3M
PCVX icon
3
Vaxcyte
PCVX
$8.81B
$35.7M 12.6%
1,405,421
– –
BOLT icon
4
Bolt Biotherapeutics
BOLT
$7.65M
$23.9M 8.46%
94,573
– –
AKUS
5
DELISTED
Akouos Inc
AKUS
$20.8M 7.36%
1,794,088
– –
INZY
6
DELISTED
Inozyme Pharma
INZY
$18.4M 6.52%
1,591,154
– –
ALGS icon
7
Aligos Therapeutics
ALGS
$45.5M
$13.6M 4.8%
35,062
– –
ARQT icon
8
Arcutis Biotherapeutics
ARQT
$3.3B
$13.6M 4.8%
569,041
– –
FUSN
9
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$12.7M 4.47%
1,598,379
+2
+0% +$17

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q3 2021 Portfolio in Review

As of Q3 2021, Pivotal bioVenture Partners Investment Advisor held 9 positions worth $283M, up 12% from $254M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $33.3M of net new capital in Q3 2021, opening 1 new position and adding to 1 existing holding. Its largest new stake was Rallybio: 283,914 shares worth $39.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pivotal bioVenture Partners Investment Advisor's largest Q3 2021 buy was Rallybio: 283,914 shares worth $39.9M.
  • Pivotal bioVenture Partners Investment Advisor added most to Fusion Pharmaceuticals Inc. Common Shares in Q3 2021, an estimated $17 increase.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $283M portfolio in Q3 2021.
  • Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 0 in Q3 2021.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 12% quarter-over-quarter to $283M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2021, filed 15 Nov 2021.